Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer 2018;18(5):269-82.
DOI: 10.1038/nrc.2018.11
Taberna M, Mena M, Pavon MA, et al. Human papillomavirus-related oropharyngeal cancer. Ann Oncol 2017;28(10):2386-98.
DOI: 10.1093/annonc/mdx304
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population-based to a more "personalized" approach to cancer staging. CA Cancer J Clin 2017;67(2):93-9.
DOI: 10.3322/caac.21388
Lechner M, Liu J, Masterson L, Fenton TR. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 2022;19(5):306-27.
DOI: 10.1038/s41571-022-00603-7
Castellsague X, Alemany L, Quer M, et al. HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients. J Natl Cancer Inst 2016;108(6):djv403.
DOI: 10.1093/jnci/djv403
Roden RBS, Stern PL. Opportunities and challenges for human papillomavirus vaccination in cancer. Nat Rev Cancer 2018;18(4):240-54.
DOI: 10.1038/nrc.2018.13
National Center for Immunization and Respiratory Diseases. Epidemiology and Prevention of Vaccine-Preventable Diseases. Human papillomavirus. Disponible en: https://www.cdc.gov/vaccines/pubs/pinkbook/hpv.html
European Medicines Agency. Human papillomavirus vaccines - Cervarix, Gardasil, Gardasil 9. Silgard. Disponible en: https://www.ema.europa.eu/en/medicines/human/referrals/human-papillomavirus-vaccines-cervarix-gardasil-gardasil-9-silgard
Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30Suppl.5(05):F123-38.
DOI: 10.1016/j.vaccine.2012.04.108
Villa A, Patton LL, Giuliano AR, et al. Summary of the evidence on the safety, efficacy, and effectiveness of human papillomavirus vaccines: Umbrella review of systematic reviews. J Am Dent Assoc 2020;151(4):245-54e24.
DOI: 10.1016/j.adaj.2019.10.010
Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-43.
DOI: 10.1056/NEJMoa061760
Group FIS. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-27.
DOI: 10.1056/NEJMoa061741
Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):89-99.
DOI: 10.1016/S1470-2045(11)70286-8
Kreimer AR, Herrero R, Sampson JN, et al. Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies. Vaccine 2018;36(32 Pt A):4774-82.
DOI: 10.1016/j.vaccine.2017.12.078
Joura E, Bautista O, Luxembourg A. A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. N Engl J Med 2015;372(26):2568-9.
Herrero R, Quint W, Hildesheim A, et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica. PLoS One 2013;8(7):e68329.
DOI: 10.1371/journal.pone.0068329
Nielsen KJ, Jakobsen KK, Jensen JS, et al. The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection-A Systematic Review. Viruses 2021;13(7).
DOI: 10.3390/v13071339
Handisurya A, Schellenbacher C, Haitel A, et al. Human papillomavirus vaccination induces neutralising antibodies in oral mucosal fluids. Br J Cancer 2016;114(4):409-16.
DOI: 10.1038/bjc.2015.462
Pinto LA, Kemp TJ, Torres BN, et al. Quadrivalent Human Papillomavirus (HPV) Vaccine Induces HPV-Specific Antibodies in the Oral Cavity: Results From the Mid-Adult Male Vaccine Trial. J Infect Dis 2016;214(8):1276-83.
DOI: 10.1093/infdis/jiw359
Giuliano AR, Wilkin T, Bautista OM, et al. Design of a phase III efficacy, immunogenicity, and safety study of 9-valent human papillomavirus vaccine in prevention of oral persistent infection in men. Contemp Clin Trials 2022;115:106592.
DOI: 10.1016/j.cct.2021.106592
Lang Kuhs KA, Wood CB, Wiggleton J, et al. Transcervical sonography and human papillomavirus 16 E6 antibodies are sensitive for the detection of oropharyngeal cancer. Cancer 2020;126(11):2658-65.
DOI: 10.1002/cncr.32799
Coquia SF, Hamper UM, Holman ME, et al. Visualization of the Oropharynx With Transcervical Ultrasound. AJR Am J Roentgenol 2015;205(6):1288-94.
DOI: 10.2214/AJR.15.14299
Salzillo TC, Taku N, Wahid KA, et al. Advances in Imaging for HPV-Related Oropharyngeal Cancer: Applications to Radiation Oncology. Semin Radiat Oncol 2021;31(4):371-88.
DOI: 10.1016/j.semradonc.2021.05.001
Piazza C, Del Bon F, Paderno A, et al. The diagnostic value of narrow band imaging in different oral and oropharyngeal subsites. Eur Arch Otorhinolaryngol 2016;273(10):3347-53.
DOI: 10.1007/s00405-016-3925-5
van Schaik JE, Halmos GB, Witjes MJH, Plaat BEC. An overview of the current clinical status of optical imaging in head and neck cancer with a focus on Narrow Band imaging and fluorescence optical imaging. Oral Oncol 2021;121:105504.
DOI: 10.1016/j.oraloncology.2021.105504
Lin Y-C, Watanabe A, Chen W-C, et al. Narrowband imaging for early detection of malignant tumors and radiation effect after treatment of head and neck cancer. Arch Otolaryngol Head Neck Surg 2010;136(3):234-9.
DOI: 10.1001/archoto.2009.230
Muto M, Nakane M, Katada C, et al. Squamous cell carcinoma in situ at oropharyngeal and hypopharyngeal mucosal sites. Cancer 2004;101(6):1375-81.
DOI: 10.1002/cncr.20482
Muto M, Minashi K, Yano T, et al. Early detection of superficial squamous cell carcinoma in the head and neck region and esophagus by narrow band imaging: a multicenter randomized controlled trial. J Clin Oncol 2010;28(9):1566-72.
DOI: 10.1200/JCO.2009.25.4680
Fakhry C, Rosenthal BT, Clark DP, Gillison ML. Associations between oral HPV16 infection and cytopathology: evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) 2011;4(9):1378-84.
DOI: 10.1158/1940-6207.CAPR-11-0284
Masterson L, Sorgeloos F, Winder D, et al. Deregulation of SYCP2 predicts early stage human papillomavirus-positive oropharyngeal carcinoma: A prospective whole transcriptome analysis. Cancer Sci 2015;106(11):1568-75.
DOI: 10.1111/cas.12809
Dahlstrom KR, Anderson KS, Cheng JN, et al. HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx. Clin Cancer Res 2015;21(12):2861-9.
DOI: 10.1158/1078-0432.CCR-14-3323
Fakhry C, Qualliotine JR, Zhang Z, et al. Serum Antibodies to HPV16 Early Proteins Warrant Investigation as Potential Biomarkers for Risk Stratification and Recurrence of HPV-Associated Oropharyngeal Cancer. Cancer Prev Res (Phila) 2016;9(2):135-41.
DOI: 10.1158/1940-6207.CAPR-15-0299
Lang Kuhs KA, Kreimer AR, Trivedi S, et al. Human papillomavirus 16 E6 antibodies are sensitive for human papillomavirus-driven oropharyngeal cancer and are associated with recurrence. Cancer 2017;123(22):4382-90.
DOI: 10.1002/cncr.30966
Kreimer AR, Johansson M, Waterboer T, et al. Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 2013;31(21):2708-15.
DOI: 10.1200/JCO.2012.47.2738
Anantharaman D, Gheit T, Waterboer T, et al. Human papillomavirus infections and upper aero-digestive tract cancers: the ARCAGE study. J Natl Cancer Inst 2013;105(8):536-45.
DOI: 10.1093/jnci/djt053
Hibbert J, Halec G, Baaken D, et al. Sensitivity and Specificity of Human Papillomavirus (HPV) 16 Early Antigen Serology for HPV-Driven Oropharyngeal Cancer: A Systematic Literature Review and Meta-Analysis. Cancers (Basel) 2021;13(12).
DOI: 10.3390/cancers13123010
Gilbert DC, Wakeham K, Langley RE, Vale CL. Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis. Br J Cancer 2019;120(2):256-68.
DOI: 10.1038/s41416-018-0273-9
Gan SJ, Dahlstrom KR, Peck BW, et al. Incidence and pattern of second primary malignancies in patients with index oropharyngeal cancers versus index nonoropharyngeal head and neck cancers. Cancer 2013;119(14):2593-601.
DOI: 10.1002/cncr.28107
Balamurugan A, Ahmed F, Saraiya M, et al. Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors. Cancer 2008;113(Suppl.10):2919-25.
DOI: 10.1002/cncr.23746
Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol 2009;27(6):967-73.
DOI: 10.1200/JCO.2008.18.4549
Saleem AM, Paulus JK, Shapter AP, et al. Risk of anal cancer in a cohort with human papillomavirus-related gynecologic neoplasm. Obstet Gynecol. 2011;117(3):643-9.
DOI: 10.1097/AOG.0b013e31820bfb16
Neumann F, Jégu J, Mougin C, et al. Risk of second primary cancer after a first potentially-human papillomavirus-related cancer: A population-based study. Prev Med 2016;90:52-8.
DOI: 10.1016/j.ypmed.2016.06.041
Péré H, Pavie J, Pernot S, et al. Comment on "Increased risk of second cancers at sites associated with HPV after a prior HPV-associated malignancy, a systematic review and meta-analysis". Br J Cancer 2019;120(9):952-3.
DOI: 10.1038/s41416-019-0439-0
Rettig EM, Wentz A, Posner MR, et al. Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma. JAMA Oncol 2015;1(7):907-15.
DOI: 10.1001/jamaoncol.2015.2524
Chuang AY, Chuang TC, Chang S, et al. Presence of HPV DNA in convalescent salivary rinses is an adverse prognostic marker in head and neck squamous cell carcinoma. Oral Oncol 2008;44(10):915-9.
DOI: 10.1016/j.oraloncology.2008.01.001
Gipson BJ, Robbins HA, Fakhry C, D'Souza G. Sensitivity and specificity of oral HPV detection for HPV-positive head and neck cancer. Oral Oncol 2018;77:52-6.
DOI: 10.1016/j.oraloncology.2017.12.008
Cao H, Banh A, Kwok S, et al. Quantitation of human papillomavirus DNA in plasma of oropharyngeal carcinoma patients. Int J Radiat Oncol Biol Phys 2012;82(3):e351-8.
DOI: 10.1016/j.ijrobp.2011.05.061
Lee JY, Garcia-Murillas I, Cutts RJ, et al. Predicting response to radical (chemo)radiotherapy with circulating HPV DNA in locally advanced head and neck squamous carcinoma. Br J Cancer 2017;117(6):876-83.
DOI: 10.1038/bjc.2017.258
Chera BS, Kumar S, Shen C, et al. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. J Clin Oncol 2020;38(10):1050-8.
DOI: 10.1200/JCO.19.02444
Honore N, van Marcke C, Galot R, et al. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck. Ann Oncol 2023;34(12):1175-86.
DOI: 10.1016/j.annonc.2023.09.3102
Mehanna H, Wong WL, McConkey CC, et al. PET-CT Surveillance versus Neck Dissection in Advanced Head and Neck Cancer. N Engl J Med 2016;374(15):1444-54.
DOI: 10.1056/NEJMoa1514493
Chera BS, Kumar S, Beaty BT, et al. Rapid Clearance Profile of Plasma Circulating Tumor HPV Type 16 DNA during Chemoradiotherapy Correlates with Disease Control in HPV-Associated Oropharyngeal Cancer. Clin Cancer Res 2019;25(15):4682-90.
DOI: 10.1158/1078-0432.CCR-19-0211
Cuschieri K, Bhatia R, Cruickshank M, et al. HPV testing in the context of post-treatment follow up (test of cure). J Clin Virol 2016;76(Suppl.1):S56-s61.
DOI: 10.1016/j.jcv.2015.10.008
Lingen MW, Abt E, Agrawal N, et al. Evidence-based clinical practice guideline for the evaluation of potentially malignant disorders in the oral cavity: A report of the American Dental Association. J Am Dent Assoc 2017;148(10):712-27.e10.
DOI: 10.1016/j.adaj.2017.07.032
Número de descargas:
4421
Número de visitas:
411
Citas:
0
